Vnitr Lek 2017, 63(9):604-608 | DOI: 10.36290/vnl.2017.120

Primary hyperparathyroidism - new clinical forms of the disease

Kateřina Zajíčková
Endokrinologický ústav, Praha

Primary hyperparathyroidism (PHPT) has been increasingly diagnosed incidentally in its asymptomatic form owing to calcium screening tests. This form of PHPT represents 80% in developed countries. Although PHPT patients are asymptomatic, target organ (bone and kidney) involvement is frequently observed. Mild PHPT is associated with a reduction of bone mineral densityand, moreover, with increased risk of vertebral fractures. The extent of a patient evaluation and indications for parathyroidectomy are based on expert guidelines from 2014. Normocalcemic variant of PHPT has been recently recognized, possibly with higher prevalence in general population than the hypercalcemic form of PHPT. Normal but with respect to hypercalcemia inadequately high parathormon levels characterize normohormonal PHPT. If a hereditary form of PHPT is suspected, genetic testing is recommended. Although there are new clinical forms of PHPT, parathyroidectomy still represents the only curative approach to PHPT followed by substantial osteoprotective effect.

Keywords: asymptomatic form; normocalcemic form; normohormonal form; parathyroidectomy; primary hyperparathyroidism; recent guidelines for the management PHPT

Received: July 28, 2017; Accepted: September 4, 2017; Published: September 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zajíčková K. Primary hyperparathyroidism - new clinical forms of the disease. Vnitr Lek. 2017;63(9):604-608. doi: 10.36290/vnl.2017.120.
Download citation

References

  1. Bilezikian JP, Cusano NE, Khan AA et al. Primary hyperparathyroidism. Nat Rev Dis Primers 2016; 2: 16033. Dostupné z DOI: <http://dx.doi.org/10.1038/nrdp.2016.33>. Go to original source... Go to PubMed...
  2. Khan AA, Hanley DA, Rizzoli R et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 2017; 28(1): 1-19. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-016-3716-2>. Go to original source... Go to PubMed...
  3. Parent X, Spielmann C, Hanser AM. "Corrected" calcium: calcium status underestimation in non-hypoalbuminemic patients and in hypercalcemic patients. Ann Biol Clin (Paris) 2009; 67(4): 411-418. Dostupné z DOI: <http://dx.doi.org/10.1684/abc.2009.0348>. Go to original source... Go to PubMed...
  4. Ong GS, Walsh JP, Stuckey BG et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 2012; 97(9): 3138-3145. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012-1429>. Go to original source... Go to PubMed...
  5. Bilezikian JP, Brandi ML, Eastell R et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99(10): 3561-3569. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-1413>. Go to original source... Go to PubMed...
  6. Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. J Clin Endocrinol Metab 2009; 94(2): 335-339. Dostupné z DOI: <http://dxdoi.org/10.1210/jc.2008-1763>. Go to original source... Go to PubMed...
  7. Silverberg SJ, Clarke BL, Peacock M et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99(10): 3580-3594. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-1415>. Go to original source... Go to PubMed...
  8. Cusano NE, Maalouf NM, Wang PY et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013; 98(7): 2734-2741. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2013-1300>. Go to original source... Go to PubMed...
  9. Šiprová H, Souček M, Fryšák Z et al. Symptomatic and asymptomatic primary hyperparathyroidism in outpatient care - current issues. Vnitř Lék 2016; 62(10): 775-780. Go to PubMed...
  10. Berger C, Almohareb O, Langsetmo L et al. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf) 2015; 82(3): 359-368. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12569>. Go to original source... Go to PubMed...
  11. Eastell R, Brandi ML, Costa AG et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99(10): 3570-3579. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-1414>. Go to original source... Go to PubMed...
  12. Applewhite MK, White MG, Tseng J et al. Normohormonal primary hyperparathyroidism is a distinct form of primary hyperparathyroidism. Surgery 2017; 161(1): 62-69. Dostupné z DOI: <http://dx.doi.org/10.1016/j.surg.2016.03.038>. Go to original source... Go to PubMed...
  13. Udelsman R, Åkerström G, Biagini C et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99(10): 3595-3606. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-2000>. Go to original source... Go to PubMed...
  14. Michaud L, Burgess A, Huchet V et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab 2014; 99(12): 4531-4536. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-2821>. Go to original source... Go to PubMed...
  15. Marcocci C, Bollerslev J, Khan AA et al. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 2014; 99(10): 3607-3618. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2014-1417>. Go to original source... Go to PubMed...
  16. Betea D, Potorac I, Beckers A. Parathyroid carcinoma: Challenges in diagnosis and treatment. Ann Endocrinol (Paris) 2015; 76(2): 169-177. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ando.2015.03.003>. Go to original source... Go to PubMed...
  17. Giusti F, Cavalli L, Cavalli T et al. Hereditary hyperparathyroidism syndromes. J Clin Densitom 2013; 16(1): 69-74. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocd.2012.11.003>. Go to original source... Go to PubMed...
  18. Cromer MK, Starker LF, Choi M et al. Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab 2012; 97(9): E1774-E1781. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012-1743>. Go to original source... Go to PubMed...
  19. Iwata S, Walker MD, Di Tullio MR et al. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2012; 97(1): 132-137. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011-2107>. Go to original source... Go to PubMed...
  20. Walker MD, McMahon DJ, Inabnet WB et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 2009; 94(6): 1951-1958. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2008-2574>. Go to original source... Go to PubMed...
  21. Verdelli C, Corbetta S. Mechanisms in endocrinology: Kidney involvement in patients with primary hyperparathyroidism: an update on clinical and molecular aspects. Eur J Endocrinol 2017; 176(1): R39-R52. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.